A recent nationwide cohort study reveals that psychotropic use in Parkinson's disease patients is significantly higher than in the general population. This trend often begins up to five years before a formal diagnosis. Consequently, non-motor symptoms may serve as early indicators of the disease. Researchers observed that the prevalence of psychotropic use in persons with Parkinson’s disease (PD) climbed from 18% to 35% over a ten-year period.

The study, conducted in Finland, matched 17,379 people with PD against a comparison cohort of over 115,000 individuals. Therefore, the findings provide a robust overview of how medication patterns evolve as the disease progresses. While benzodiazepines and related drugs (BZDRs) were the most common psychotropics used initially, antidepressants became more prevalent three years after diagnosis. This shift highlights the changing neuropsychiatric needs of patients as they navigate the complexities of PD.

Mitigating Risks of Psychotropic Use in Parkinson's Disease

Managing non-motor symptoms is crucial for patient well-being. However, the high rate of psychotropic polypharmacy—which doubled from 5% to 10% in the PD cohort—raises serious safety concerns. Healthcare providers must remain vigilant because these medications significantly increase the risk of adverse events, including falls and hip fractures. Therefore, a careful balance between treating psychiatric symptoms and maintaining motor stability remains essential for improving patient quality of life.

In the Indian clinical context, primary care physicians often manage these patients due to limited specialized care. Furthermore, local studies indicate that non-motor symptoms like depression and anxiety are frequently highly prevalent. Consequently, early screening for these symptoms, alongside a cautious approach to prescribing psychotropics, is vital for holistic patient management. Clinicians should prioritize regular medication reviews to reduce the burden of polypharmacy.

Frequently Asked Questions

Why is psychotropic use so high before a Parkinson’s diagnosis?

Non-motor symptoms, such as anxiety and depression, often precede the motor symptoms of Parkinson’s disease by several years. Consequently, patients may receive psychotropic prescriptions for these prodromal symptoms before clinicians formally identify the underlying neurological condition.

What are the primary risks associated with psychotropic polypharmacy in PD?

The main concerns include an increased risk of falls, fall-related fractures, and cognitive impairment. Additionally, certain psychotropics can worsen motor symptoms or interact negatively with dopaminergic therapies, complicating the overall treatment regimen.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Nieminen N et al. Psychotropic medication use among community dwellers with and without Parkinson's disease - A nationwide cohort study. Br J Clin Pharmacol. 2026 Apr 04. doi: 10.1002/bcp.70553. PMID: 41934204.


2. Orayj K. Trends in Parkinson's disease medication prescribing patterns in the UK: An interrupted time series analysis (2019–2024). PMC. 2025 May 23.


3. Shah J, Joshi P, Sood SV, et al. Drug utilization pattern and analysis of quality of life in Indian patients of Parkinson's disease. Int J Basic Clin Pharmacol. 2019 Aug;8(9):2062-2067. doi: 10.18203/2319-2003.ijbcp20194121.